Literature DB >> 21866356

Hearing loss in patients with mucopolysaccharidosis II: data from HOS - the Hunter Outcome Survey.

Annerose Keilmann1, Todsaporn Nakarat, Iain A Bruce, David Molter, Gunilla Malm.   

Abstract

BACKGROUND: Subjectively reported hearing loss is a common feature of mucopolysaccharidosis II (MPS II, Hunter syndrome). This study provides an epidemiological description of hearing loss and other otolaryngological manifestations reported by patients registered in the Hunter Outcome Survey (HOS), an international registry of patients with MPS II.
METHODS: Data about ear signs and symptoms were available for 554 of the 605 patients alive at HOS entry. The degree of hearing loss for 162 pure-tone audiograms (PTAs) from 83 patients was classified by independent interpreters using both the age-specific International Institute of Standardization (ISO) 7029 standard and the age-independent World Health Organization (WHO) clinical guidelines. A linear regression analysis using cross-sectional data was conducted to investigate the relationship between hearing loss and age.
RESULTS: The most prevalent otolaryngological manifestations and interventions reported were otitis (either acute otitis media or chronic otitis media [72%]), hearing loss (67%), insertion of ventilation tubes (50%), adenoidectomy (47%), and hearing aids (41%). According to the ISO standard, only one patient out of the 83 with audiogram data in HOS had normal hearing in both ears at all time points. According to the WHO classification, 16% had normal hearing; hearing loss was mild in 24%, moderate in 31%, severe in 22%, and profound in 7%. In the linear regression analysis, the hearing threshold in the cohort increased with age at an estimated rate of approximately 1 dB per year.
CONCLUSIONS: Hearing impairment is common in MPS II. Early otolaryngological evaluation and intervention is recommended.

Entities:  

Mesh:

Year:  2011        PMID: 21866356     DOI: 10.1007/s10545-011-9378-5

Source DB:  PubMed          Journal:  J Inherit Metab Dis        ISSN: 0141-8955            Impact factor:   4.982


  24 in total

1.  Long-term ventilation of the middle ear using a subannular tympanotomy technique: a follow-up study.

Authors:  P Jassar; A Coatesworth; D R Strachan
Journal:  J Laryngol Otol       Date:  2004-12       Impact factor: 1.469

2.  Cumulative incidence rates of the mucopolysaccharidoses in Germany.

Authors:  F Baehner; C Schmiedeskamp; F Krummenauer; E Miebach; M Bajbouj; C Whybra; A Kohlschütter; C Kampmann; M Beck
Journal:  J Inherit Metab Dis       Date:  2005       Impact factor: 4.982

3.  ABR and temporal bone pathology in Hurler's disease.

Authors:  Y Komura; K Kaga; Y Ogawa; Y Yamaguchi; T Tsuzuku; J I Suzuki
Journal:  Int J Pediatr Otorhinolaryngol       Date:  1998-03-01       Impact factor: 1.675

4.  Two cases of Hunter's syndrome--the anaesthetic and operative difficulties in oral surgery.

Authors:  R Hopkins; J A Watson; J H Jones; M Walker
Journal:  Br J Oral Surg       Date:  1973-03

Review 5.  Hearing Impairment in 2008: a compilation of available epidemiological studies.

Authors:  Donatella Pascolini; Andrew Smith
Journal:  Int J Audiol       Date:  2009       Impact factor: 2.117

6.  Initial report from the Hunter Outcome Survey.

Authors:  J Edmond Wraith; Michael Beck; Roberto Giugliani; Joe Clarke; Rick Martin; Joseph Muenzer
Journal:  Genet Med       Date:  2008-07       Impact factor: 8.822

7.  The natural history of the severe form of Hunter's syndrome: a study based on 52 cases.

Authors:  I D Young; P S Harper
Journal:  Dev Med Child Neurol       Date:  1983-08       Impact factor: 5.449

8.  Ear symptoms in children with Fabry disease: data from the Fabry Outcome Survey.

Authors:  A Keilmann; D Hajioff; U Ramaswami
Journal:  J Inherit Metab Dis       Date:  2009-10-27       Impact factor: 4.982

9.  The otologic manifestations of mucopolysaccharidoses.

Authors:  E Hayes; R Babin; C Platz
Journal:  Am J Otol       Date:  1980-10

10.  Histopathological studies of the temporal bones in Hurler's disease [mucopolysaccharidosis (MPS) IH].

Authors:  I Friedmann; E Spellacy; J Crow; R W Watts
Journal:  J Laryngol Otol       Date:  1985-01       Impact factor: 1.469

View more
  22 in total

1.  The Hunter syndrome-functional outcomes for clinical understanding scale (HS-FOCUS) questionnaire: evaluation of measurement properties.

Authors:  Ingela Wiklund; Mireia Raluy-Callado; Donald E Stull; Yvonne Jangelind; David A H Whiteman; Wen-Hung Chen
Journal:  Qual Life Res       Date:  2012-05-19       Impact factor: 4.147

2.  Diagnosing Hunter syndrome in pediatric practice: practical considerations and common pitfalls.

Authors:  Barbara K Burton; Roberto Giugliani
Journal:  Eur J Pediatr       Date:  2012-03-01       Impact factor: 3.183

3.  The impact of Hunter syndrome (mucopolysaccharidosis type II) on health-related quality of life.

Authors:  Mireia Raluy-Callado; Wen-Hung Chen; David A H Whiteman; Juanzhi Fang; Ingela Wiklund
Journal:  Orphanet J Rare Dis       Date:  2013-07-10       Impact factor: 4.123

4.  Diagnosis, quality of life, and treatment of patients with Hunter syndrome in the French healthcare system: a retrospective observational study.

Authors:  Nathalie Guffon; Bénédicte Heron; Brigitte Chabrol; François Feillet; Vincent Montauban; Vassili Valayannopoulos
Journal:  Orphanet J Rare Dis       Date:  2015-04-12       Impact factor: 4.123

Review 5.  Ten years of the Hunter Outcome Survey (HOS): insights, achievements, and lessons learned from a global patient registry.

Authors:  Joseph Muenzer; Simon A Jones; Anna Tylki-Szymańska; Paul Harmatz; Nancy J Mendelsohn; Nathalie Guffon; Roberto Giugliani; Barbara K Burton; Maurizio Scarpa; Michael Beck; Yvonne Jangelind; Elizabeth Hernberg-Stahl; Maria Paabøl Larsen; Tom Pulles; David A H Whiteman
Journal:  Orphanet J Rare Dis       Date:  2017-05-02       Impact factor: 4.123

Review 6.  Guidelines for diagnosis and treatment of Hunter Syndrome for clinicians in Latin America.

Authors:  Roberto Giugliani; Martha Luz Solano Villarreal; C Araceli Arellano Valdez; Antonieta Mahfoud Hawilou; Norberto Guelbert; Luz Norela Correa Garzón; Ana Maria Martins; Angelina Acosta; Juan Francisco Cabello; Aída Lemes; Mara Lucia Schmitz Ferreira Santos; Hernán Amartino
Journal:  Genet Mol Biol       Date:  2014-06       Impact factor: 1.771

7.  Clinical outcomes in idursulfase-treated patients with mucopolysaccharidosis type II: 3-year data from the hunter outcome survey (HOS).

Authors:  Joseph Muenzer; Roberto Giugliani; Maurizio Scarpa; Anna Tylki-Szymańska; Virginie Jego; Michael Beck
Journal:  Orphanet J Rare Dis       Date:  2017-10-03       Impact factor: 4.123

Review 8.  Development of idursulfase therapy for mucopolysaccharidosis type II (Hunter syndrome): the past, the present and the future.

Authors:  David Ah Whiteman; Alan Kimura
Journal:  Drug Des Devel Ther       Date:  2017-08-23       Impact factor: 4.162

9.  Hearing loss in children with Fabry disease.

Authors:  E Suntjens; W A Dreschler; J Hess-Erga; R Skrunes; F A Wijburg; G E Linthorst; C Tøndel; M Biegstraaten
Journal:  J Inherit Metab Dis       Date:  2017-05-31       Impact factor: 4.982

10.  Intrafamilial variability in the clinical manifestations of mucopolysaccharidosis type II: Data from the Hunter Outcome Survey (HOS).

Authors:  Can Ficicioglu; Roberto Giugliani; Paul Harmatz; Nancy J Mendelsohn; Virginie Jego; Rossella Parini
Journal:  Am J Med Genet A       Date:  2017-12-06       Impact factor: 2.802

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.